JP6505016B2 - 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 - Google Patents

強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 Download PDF

Info

Publication number
JP6505016B2
JP6505016B2 JP2015538330A JP2015538330A JP6505016B2 JP 6505016 B2 JP6505016 B2 JP 6505016B2 JP 2015538330 A JP2015538330 A JP 2015538330A JP 2015538330 A JP2015538330 A JP 2015538330A JP 6505016 B2 JP6505016 B2 JP 6505016B2
Authority
JP
Japan
Prior art keywords
mva
promoter
virus
seq
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015538330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533841A5 (https=
JP2015533841A (ja
Inventor
シュタイガーヴァルト・ロービン
ブリンクマン・カーイ
Original Assignee
バヴァリアン・ノルディック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バヴァリアン・ノルディック・アクティーゼルスカブ filed Critical バヴァリアン・ノルディック・アクティーゼルスカブ
Publication of JP2015533841A publication Critical patent/JP2015533841A/ja
Publication of JP2015533841A5 publication Critical patent/JP2015533841A5/ja
Application granted granted Critical
Publication of JP6505016B2 publication Critical patent/JP6505016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015538330A 2012-10-28 2013-10-28 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 Active JP6505016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719429P 2012-10-28 2012-10-28
US61/719,429 2012-10-28
PCT/EP2013/003239 WO2014063832A1 (en) 2012-10-28 2013-10-28 Pr13.5 promoter for robust t-cell and antibody responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019054129A Division JP6818797B2 (ja) 2012-10-28 2019-03-22 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答

Publications (3)

Publication Number Publication Date
JP2015533841A JP2015533841A (ja) 2015-11-26
JP2015533841A5 JP2015533841A5 (https=) 2016-10-20
JP6505016B2 true JP6505016B2 (ja) 2019-04-24

Family

ID=49513897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015538330A Active JP6505016B2 (ja) 2012-10-28 2013-10-28 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
JP2019054129A Active JP6818797B2 (ja) 2012-10-28 2019-03-22 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019054129A Active JP6818797B2 (ja) 2012-10-28 2019-03-22 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答

Country Status (26)

Country Link
US (2) US9828414B2 (https=)
EP (2) EP2912183B1 (https=)
JP (2) JP6505016B2 (https=)
KR (2) KR102135818B1 (https=)
CN (1) CN104755622B (https=)
AU (1) AU2013337018B2 (https=)
BR (1) BR112015009320A2 (https=)
CA (1) CA2887623C (https=)
CY (1) CY1123181T1 (https=)
DK (1) DK2912183T3 (https=)
EA (2) EA201990114A1 (https=)
ES (1) ES2800623T3 (https=)
HK (1) HK1212383A1 (https=)
HU (1) HUE049706T2 (https=)
IL (1) IL238130B (https=)
IN (1) IN2015DN03326A (https=)
LT (1) LT2912183T (https=)
MX (2) MX380483B (https=)
MY (2) MY194609A (https=)
NZ (1) NZ706637A (https=)
PT (1) PT2912183T (https=)
SG (2) SG10201704657WA (https=)
SI (1) SI2912183T1 (https=)
UA (1) UA118340C2 (https=)
WO (1) WO2014063832A1 (https=)
ZA (1) ZA201502892B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9828414B2 (en) * 2012-10-28 2017-11-28 Bavarian Nordic A/S Pr13.5 promoter for robust T-cell and antibody responses
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US10881725B2 (en) 2016-01-29 2021-01-05 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
CA3036799C (en) 2016-09-28 2025-05-13 Bavarian Nordic A/S COMPOSITIONS AND METHODS FOR IMPROVING THE STABILITY OF TRANSGENES IN POXVIRUSES
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
KR102754876B1 (ko) 2017-08-24 2025-01-13 버베리안 노딕 에이/에스 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법
CN111741766A (zh) 2017-12-19 2020-10-02 杨森科学爱尔兰无限公司 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
GB201807932D0 (en) 2018-05-16 2018-06-27 Redchenko Irina Compositions and methods for inducing an immune response
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CN110904127B (zh) 2018-09-18 2024-09-20 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
JP7555334B2 (ja) 2018-10-05 2024-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
MX2021005560A (es) 2018-11-20 2021-06-23 Bavarian Nordic As Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l).
CN114867491B (zh) 2019-11-20 2025-08-15 巴法里安诺迪克有限公司 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒
CA3181431A1 (en) 2020-06-10 2021-12-16 Jurgen Hausmann A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
IL311078A (en) 2021-09-03 2024-04-01 Bavarian Nordic As Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva)
US20250049903A1 (en) 2021-12-23 2025-02-13 Bavarian Nordic A/S Therapy for Modulating Immune Response with Recombinant MVA Encoding IL-12
EP4452305A1 (en) 2021-12-23 2024-10-30 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
JP2025525380A (ja) 2022-06-29 2025-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換え改変ｓａＲＮＡ（ＶＲＰ）及びワクシニアウイルスアンカラ（ＭＶＡ）プライム－ブーストレジメン
CA3261778A1 (en) 2022-08-18 2024-02-22 Transgene CHIMERIC POXVIRUSES
EP4648781A1 (en) 2023-01-12 2025-11-19 Bavarian Nordic A/S Recombinant modified sarna (vrp) for cancer vaccine
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
WO2025238218A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Viral vectors encoding antigen-displaying protein nanoparticles
WO2025238219A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Modified vaccinia virus ankara (mva) encoding antigen-displaying protein nanoparticles
WO2025238220A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Nucleic acids for vaccination encoding antigen-displaying protein nanoparticles
WO2025238221A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Viral vectors encoding multi-antigen-displaying protein nanoparticles
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9922361D0 (en) * 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
ES2424847T3 (es) 2004-06-25 2013-10-09 Merial Ltd. Genes del virus de la fiebre aftosa que expresan avipox recombinantes
JP2008301792A (ja) 2007-06-11 2008-12-18 National Univ Corp Shizuoka Univ 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法
JP2012509678A (ja) 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US9828414B2 (en) * 2012-10-28 2017-11-28 Bavarian Nordic A/S Pr13.5 promoter for robust T-cell and antibody responses

Also Published As

Publication number Publication date
CN104755622B (zh) 2021-04-20
EP2912183A1 (en) 2015-09-02
MX2015005264A (es) 2015-07-17
US20150299267A1 (en) 2015-10-22
EP3778904A1 (en) 2021-02-17
LT2912183T (lt) 2020-07-27
AU2013337018B2 (en) 2019-09-05
MX2021001638A (es) 2021-05-12
IN2015DN03326A (https=) 2015-10-09
JP6818797B2 (ja) 2021-01-20
KR20200087880A (ko) 2020-07-21
JP2019131572A (ja) 2019-08-08
BR112015009320A2 (pt) 2017-10-17
US11028130B2 (en) 2021-06-08
ZA201502892B (en) 2020-08-26
JP2015533841A (ja) 2015-11-26
KR102135818B1 (ko) 2020-07-22
CA2887623A1 (en) 2014-05-01
ES2800623T3 (es) 2021-01-04
US9828414B2 (en) 2017-11-28
HUE049706T2 (hu) 2020-10-28
EA201990114A1 (ru) 2019-09-30
MY194609A (en) 2022-12-06
EA201590831A1 (ru) 2015-08-31
SG10201704657WA (en) 2017-07-28
EA032498B1 (ru) 2019-06-28
SG11201503200PA (en) 2015-05-28
UA118340C2 (uk) 2019-01-10
IL238130A0 (en) 2015-05-31
AU2013337018A9 (en) 2018-08-30
WO2014063832A1 (en) 2014-05-01
AU2013337018A1 (en) 2015-04-30
KR20150079596A (ko) 2015-07-08
US20180111966A1 (en) 2018-04-26
EP2912183B1 (en) 2020-05-06
CY1123181T1 (el) 2021-10-29
MY171687A (en) 2019-10-23
CN104755622A (zh) 2015-07-01
CA2887623C (en) 2021-02-16
HK1212383A1 (en) 2016-06-10
IL238130B (en) 2019-09-26
DK2912183T3 (da) 2020-07-27
MX380483B (es) 2025-03-12
NZ706637A (en) 2019-02-22
PT2912183T (pt) 2020-06-05
SI2912183T1 (sl) 2020-07-31

Similar Documents

Publication Publication Date Title
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
CN102341120B (zh) 结合重复免疫的优化早晚期启动子辅助对复制缺陷型重组病毒疫苗抗原的细胞毒t细胞应答
US10111946B2 (en) Poxviral vectors for low antibody response after a first priming immunization
US9163237B2 (en) Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
AU2017228587B2 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
HK40044708A (en) Pr13.5 promoter for robust t-cell and antibody responses
EA045254B1 (ru) Промотор pr13.5 для устойчивых т-клеточных и гуморальных иммунных реакций
HK1161677B (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190326

R150 Certificate of patent or registration of utility model

Ref document number: 6505016

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250